title: Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population.
abstract: An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n = 88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1 mg/kg) (n = 27) or thymoglobulin alone (4-7 doses; 1 mg/kg) (n = 23). SPK recipients received daclizumab (two doses; 1 mg/kg) in addition to thymoglobulin (five doses; 1 mg/kg). The return of peripheral blood CD25+ cells was delayed for 45 d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.
authors.affiliation: Division of Kidney and Pancreas Transplantation, Department of Surgery, University of Miami, Miller School of Medicine, 1801 NW 9th Ave., 5th Fl., Miami, FL 33136, USA.
authors.forename: Junichiro
authors.initials: J
authors.lastname: Sageshima
authors.forename: Gaetano
authors.initials: G
authors.lastname: Ciancio
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Gaynor
authors.forename: Linda
authors.initials: L
authors.lastname: Chen
authors.forename: Giselle
authors.initials: G
authors.lastname: Guerra
authors.forename: Warren
authors.initials: W
authors.lastname: Kupin
authors.forename: David
authors.initials: D
authors.lastname: Roth
authors.forename: Phillip
authors.initials: P
authors.lastname: Ruiz
authors.forename: George W
authors.initials: GW
authors.lastname: Burke
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000077561:Daclizumab; D005434:Flow Cytometry; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood*; D016030:Kidney Transplantation; D018655:Lymphocyte Count; D016035:Pancreas Transplantation; D016176:T-Lymphocyte Subsets
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; C508017:IL2RA protein, human; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053645:Interleukin-2 Receptor alpha Subunit; D000077561:Daclizumab; C512542:thymoglobulin